BACKGROUND: The functional changes that occur over time in the liver following 90Y-radioembolization (RE) using personalized dosimetry (PD) remain to be investigated. METHODS: November 2016-October 2019: we retrospectively included hepatocellular carcinoma (HCC) patients treated by 90Y-glass RE using PD, who underwent hepatobiliary scintigraphy (HBS) at baseline and at 15 days, 1, 2, 3, and 6 months after RE. RESULTS: There were 16 patients with unilobar disease (100%) included, and 64 HBS were performed. Whole liver function significantly decreased over time. The loss was maximal at 2 weeks: -32% (p = 0.002) and remained below baseline at 1 (-15%; p = 0.002), 2 (-25%; p < 0.001), and 3 months (-16%; p = 0.027). No radioembolization-induced liver disease was observed. Treated liver function strongly decreased to reach -64% (p < 0.001) at 2 months. Nontreated liver function decreased at 2 weeks (-21%; p = 0.027) and remained below baseline before reaching +20% (p = 0.002) and +59% (p < 0.001) at 3 and 6 months, respectively. Volumetric and functional changes exhibited parallel evolutions in the treated livers (p = 0.01) but independent evolutions in the nontreated livers (p = 0.08). CONCLUSION: RE using PD induces significant regional changes in liver function over time. As early as 15 days following RE, both the treated and nontreated livers showed a decreased function. Nontreated liver function recovered after 3 months and greatly increased afterwards.
BACKGROUND: The functional changes that occur over time in the liver following 90Y-radioembolization (RE) using personalized dosimetry (PD) remain to be investigated. METHODS: November 2016-October 2019: we retrospectively included hepatocellular carcinoma (HCC) patients treated by 90Y-glass RE using PD, who underwent hepatobiliary scintigraphy (HBS) at baseline and at 15 days, 1, 2, 3, and 6 months after RE. RESULTS: There were 16 patients with unilobar disease (100%) included, and 64 HBS were performed. Whole liver function significantly decreased over time. The loss was maximal at 2 weeks: -32% (p = 0.002) and remained below baseline at 1 (-15%; p = 0.002), 2 (-25%; p < 0.001), and 3 months (-16%; p = 0.027). No radioembolization-induced liver disease was observed. Treated liver function strongly decreased to reach -64% (p < 0.001) at 2 months. Nontreated liver function decreased at 2 weeks (-21%; p = 0.027) and remained below baseline before reaching +20% (p = 0.002) and +59% (p < 0.001) at 3 and 6 months, respectively. Volumetric and functional changes exhibited parallel evolutions in the treated livers (p = 0.01) but independent evolutions in the nontreated livers (p = 0.08). CONCLUSION: RE using PD induces significant regional changes in liver function over time. As early as 15 days following RE, both the treated and nontreated livers showed a decreased function. Nontreated liver function recovered after 3 months and greatly increased afterwards.
Authors: Jens Ricke; Heinz Josef Klümpen; Holger Amthauer; Irene Bargellini; Peter Bartenstein; Enrico N de Toni; Antonio Gasbarrini; Maciej Pech; Markus Peck-Radosavljevic; Peter Popovič; Olivier Rosmorduc; Eckart Schott; Max Seidensticker; Chris Verslype; Bruno Sangro; Peter Malfertheiner Journal: J Hepatol Date: 2019-08-14 Impact factor: 25.083
Authors: Sandra van der Velden; Manon N G J A Braat; Tim A Labeur; Mike V Scholten; Otto M van Delden; Roelof J Bennink; Hugo W A M de Jong; Marnix G E H Lam Journal: J Nucl Med Date: 2019-04-06 Impact factor: 10.057
Authors: Kasia P Cieslak; Roelof J Bennink; Wilmar de Graaf; Krijn P van Lienden; Marc G Besselink; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik Journal: HPB (Oxford) Date: 2016-07-25 Impact factor: 3.647
Authors: Deha Erdogan; Bob H M Heijnen; Roelof J Bennink; Mariël Kok; Sander Dinant; Irene H Straatsburg; Dirk J Gouma; Thomas M van Gulik Journal: Liver Int Date: 2004-04 Impact factor: 5.828
Authors: Thiery Chapelle; Bart Op De Beeck; Ivan Huyghe; Sven Francque; Ann Driessen; Geert Roeyen; Dirk Ysebaert; Kathleen De Greef Journal: HPB (Oxford) Date: 2016-03-21 Impact factor: 3.647
Authors: Manon N G J A Braat; Hugo W de Jong; Beatrijs A Seinstra; Mike V Scholten; Maurice A A J van den Bosch; Marnix G E H Lam Journal: EJNMMI Res Date: 2017-01-05 Impact factor: 3.138
Authors: Marnix Lam; Etienne Garin; Marco Maccauro; S Cheenu Kappadath; Daniel Y Sze; Cuneyt Turkmen; Murat Cantasdemir; Paul Haste; Ken Herrmann; Hamad Saleh Alsuhaibani; Matthew Dreher; Kirk D Fowers; Riad Salem Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-08 Impact factor: 10.057